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The risk of an adverse outcome to pregnancy is increased in women with epilepsy. This is partly attributable to antiepileptic
drugs. Guidelines for the management of pregnancy in women with epilepsy generally advise against polytherapy but make
no distinction between the risks of different drugs. Several recent studies have however shown greater risk of adverse outcome
in offspring exposed to sodium valproate in utero, particularly at higher doses. The outcome of pregnancy was monitored
to identify antiepileptic drug treatment associated with a poor outcome in a mainly prospective study of women attending
an outpatient clinic. From January 1990 to December 1999 all 69 pregnancies in women referred to the clinic were mon-
itored. Drug treatments and other risk factors were recorded. In each child dysmorphic features, developmental delay and
structural anomalies were assessed and graded. Data were analysed for drug- and dosage-dependent differences in outcome.
In each assessment area a positive association between adverse outcome and dose was found for sodium valproate but not for
carbamazepine. Severe adverse outcomes were found only in children exposed to sodium valproate at maternal doses above
1000 mg per day.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
The risk of an adverse outcome to pregnancy is
greater in women with epilepsy than in the general
population1. This is partly attributable to antiepileptic
drug treatment. Guidelines for the management of
pregnancy in women with epilepsy1–4 consistently
advise against polytherapy but generally make no
distinction between the risks of different antiepileptic
drugs (AEDs) when given as monotherapy.
Recently however several studies have shown a
greater risk of adverse outcome in offspring exposed
to higher doses of sodium valproate in utero (see
Discussion) and the Royal College of Physicians of
London2 has advised the avoidance of ‘high daily
doses of valproate, e.g. more than 1000 mg per day’
before conception in the interest of risk reduction.
Similarly the Epilim data sheet5 from 1998 onwards
acknowledges that ‘abnormal pregnancy outcome
tends to be associated with higher total daily dosage’.
We report here the results of monitoring pregnan-
cies prospectively over a 10-year period in women
attending an epilepsy clinic at a teaching hospital.
Although patient numbers were not large they did per-
mit comparison between carbamazepine and sodium
valproate, when each was given as monotherapy. The
worst affected offspring were those exposed to higher
doses of the latter; a small number of these cases
were assessed retrospectively.
PATIENTS AND METHODS
Forty-five mothers, pregnant between January 1990
and December 1999, attended the Epilepsy Clinic
at the Manchester Royal Infirmary. Twenty-six had
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focal epilepsy (F), 17 had idiopathic generalised
epilepsy (IG) and in 2 the epilepsy was unclassified
(UC). Maternal epilepsy syndrome diagnoses were
based on seizure history including description by a
witness, EEG and brain imaging; they are indicated
in Tables 2–4.
In all but four instances the pregnancies were
assessed prospectively. Most women were under
the care of the clinic before conception but about
one-third were already pregnant at referral. Four
women were referred for advice after bad outcomes to
earlier pregnancies; these were assessed in retrospect
and compared with the outcome of subsequent preg-
nancies after drug treatment changes. The study in-
cluded every pregnancy known to the medical/nursing
staff in women attending the clinic; there were no
exclusions.
Children
Of 69 pregnancies, 10 were lost. Fifty-nine babies (25
male, 34 female) were born but 2 mothers with idio-
pathic generalised epilepsy (IG) refused assessment of
their 3 children (1 exposed to sodium valproate, 2 to
polytherapy) and 56 children were assessed by a con-
sultant clinical geneticist. Age at assessment ranged
from 4 months to 10 years. No specific genetic syn-
drome was identified in any of the children. The as-
sessors of the children had no direct involvement with
the clinical care of the mother but no steps were taken
to conceal her history and drug treatment from the as-
sessor.
Assessment
The condition of each child was assessed in three
areas—dysmorphic features, developmental delay and
structural anomalies. In each area the severity of ad-
Table 1: Grading of an adverse outcome: each child was assessed in three areasa.
Grade Dysmorphic Developmental delay Structural anomalies
features
0 None None None
1: Mild 1–3 Milestones attained after a delay Minor anomaly but no disability,
e.g. inguinal hernia
2: Moderate 4–6 Mild learning difficulty special
educational needs
Minor anomaly with disability, e.g. talipes
3: Severe >6 Moderate to severe learning difficulty Major anomaly, e.g. neural tube defect
cleft palate, coloboma
Dysmorphic features included prominent midline ridge to forehead, wide set eyes, epicanthic folds, flat nasal bridge, upturned nose, flat
philtrum, dysplastic ears, down turned mouth, hypoplastic nails, overlapping digits. The score in this assessment area was the number of
features identified.
a The severity of adverse features was graded on a discontinuous scale according to the criteria shown.
verse outcome was graded on a discontinuous scale—
0 none, 1 mild, 2 moderate, 3 severe. The basis of this
grading is shown in Table 1.
Dysmorphic features (prominent midline ridge to
forehead, wide set eyes, epicanthic folds, flat nasal
bridge, upturned nose, flat philtrum, dysplastic ears,
down turned mouth, hypoplastic nails, overlapping
digits) were listed and counted; the more numerous the
features, the more severe the degree of dysmorphism.
Developmental delay was rated as mild if the child
did attain normal milestones albeit at an older age than
usual. Developmental delay was moderate if special
educational needs had been identified and extra help
was needed for the child to acquire skills; there was
often a formal Statement of Special Needs. Delay was
rated as severe when there was little or no speech
and the child remained dependent on others for most
aspects of daily living.
Structural anomalies were rated as mild (for exam-
ple capillary naevus or inguinal hernia) when they
produced no disability. Anomalies were moderate (tal-
ipes, hip dislocation) when intervention was needed
to prevent physical disability. They were rated as se-
vere when there was failure of embryonic fusion (car-
diac septal defect, cleft hand, cleft palate, coloboma of
the iris, hypospadias, spina bifida) or agenesis (radial
ray deficiency). Surgical treatment was often needed
within this group.
There was no control group of mothers who had no
history of epilepsy but within the population of women
with epilepsy comparisons were made between differ-
ent treatment groups (sodium valproate monotherapy,
carbamazepine monotherapy and polytherapy). Dif-
ferences between valproate and carbamazepine in the
distribution of drug doses were assessed by variance
ratio. Since the severity of adverse outcome (Table 1)
was not a continuous measure, the strength of an as-
sociation between adverse outcome and drug dose for
example was assessed using the Spearman rank cor-
relation coefficient6.
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RESULTS
In 69 pregnancies antiepileptic drugs were prescribed,
as follows:
no drug 1 pregnancy in a woman with partial seizures only
monotherapy Sodium valproate (VPS), 23 pregnancies in 14 women (IG/F/UC = 9/4/1)
Carbamazepine (CBZ), 18 pregnancies in 13 women (IG/F/UC = 0/12/1)
Phenytoin (PHT), 7 pregnancies in 3 women (IG/F/UC = 0/3/0)
Lamotrigine (LTG), 4 pregnancies in 3 women (IG/F/UC = 1/2/0)
Ethosuximide (ESM), 1 pregnancy in a woman with IG epilepsy
polytherapy Combined AED including the above, 15 pregnancies in 12 women (IG/F/UC = 6/6/0)
The total number of women listed above (47) ex-
ceeds the 45 stated earlier because 2 women who were
switched from VPS to alternative treatment before a
subsequent pregnancy each appear twice in different
drug treatment groups.
Ten drug-exposed foetuses were lost—one ectopic
pregnancy, five spontaneous miscarriages at 5, 8, 11,
12, and 19 weeks, one intrauterine death at 26 weeks
and three terminations because of spina bifida.
The assessments of the 56 children and the three
cases of spina bifida are summarised in Fig. 1a. Dys-
morphic features were found in more than half the
children and there was some evidence of developmen-
tal delay in about one-quarter. Structural anomalies
were found in about one-third of offspring. In each
area of assessment the adverse features were usually
mild but in about 10% they were moderate or severe.
Delayed development was associated with dysmorphic
features (Spearman rank correlation coefficient 0.38,
P < 0.01, N = 56) but not with structural anoma-
lies (rank correlation coefficient 0.08, P = 0.57,
N = 56).
Folic acid at 5.0 mg per day was taken before con-
ception by 24 women and at 0.4 mg per day by 3
women. There was a significant negative correlation
with the dose of folic acid for structural anomalies
(Spearman rank correlation coefficient −0.263, P =
0.04, N = 59) but not for dysmorphic features (P =
0.55, N = 56) or delayed development (P = 0.49,
N = 56).
Monotherapy with sodium valproate
The daily dose of VPS prescribed before conception
is shown in Table 2; it ranged widely from 200 to
3000 mg (mean± SD 1236± 771, coefficient of vari-
ation 0.623, N = 22). One woman with myoclonic
epilepsy (case 41(i)) prescribed 3000 mg per day,
had no detectable VPS in plasma twice during preg-
nancy. Plasma VPS was not measured in every patient
however.
The outcomes of individual pregnancies in the three
assessment areas are shown in Table 2. A moderate
or severe adverse outcome in at least one assessment
area was found in eight offspring.
In each assessment area a positive association
was found between adverse outcome and VPS dose
(Table 5). The significance was borderline for devel-
opmental delay but high for the other two areas. At
doses below 1000 mg per day adverse features were
absent or mild but at higher doses moderate or severe
adverse features were found in one area of assessment
at least, in half the children.
Fig. 1: Adverse features in the offspring of mothers with
epilepsy: this shows the proportion (%) of the offspring in
whom dysmorphic features (Dysmorph), developmental
delay (Dev Delay) and structural anomalies (Struct) were
found. Severity was graded as shown in Table 1. The total
group (a) includes three cases of spina bifida, where
termination of pregnancy restricted the assessment to the
structural anomaly. The effect of excluding the 12 offspring
exposed to maternal doses of sodium valproate greater
than 1000 mg per day (in mono- or polytherapy) is shown in
(b) moderate adverse features were reduced and severe
adverse features were removed.
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Table 2: Dose of sodium valproate taken by the mother at conception and severity of the adverse features observed in the child.
Dose (mg per day) Dysmorphic features Developmental delay Structural anomalies
Prospective cases
2 F (ii)m 0 0 0 0
14 IG (ii)f 200 1 0 1
14 IG (iii)f 200 0 0 0
14 IG (i) 300 – – – (M)
6 IG (ii)f 400 0 0 0
33 IG (i)f 600 1 0 0
5 IG (i)m 600 0 1 0
5 IG (ii)m 600 0 1 1
28 IG (i)f 800 1 0 0
7 F (ii)f 800 1 0 1
13 IG (ii)f 1000 2 1 0
13 IG (i)f 1200 2 1 0
16 IG (ii)f 1200 0 0 0
16 IG (i)f 1400 1 0 0
7 F (i) 1600 – (M)
15 UC (i)m 1800 2 2 3
41 IG (i)f 3000 1 0 0
Retrospective cases
6 IG (i)f 1400 1 2 0
10 F (i) 1600 – – 3 (T)
11 F (i) 2000 – – 3 (T)
11 F (ii) 2000 – – – (M)
11 F (i)f 2000 2 1 2
2 F (i)m 2500 3 3 3
Mother—study acquisition number 2–41; epilepsy syndrome F: focal, IG: idiopathic generalised, UC: unclassified. Child—number of
pregnancy (i)–(iii); m/f: gender; adverse features 0: none, 1: mild, 2: moderate, 3: severe, (M): miscarriage, (T): termination.
Four women on VPS were referred for advice about
medication before a future pregnancy; they each had
adverse outcomes to earlier pregnancies on doses of
1400–2500 mg per day (retrospective cases, Table 2).
After withdrawal of AED, reduction of VPS dose or
transfer to CBZ, three of these women conceived again
with a normal outcome (cases 2(ii) and 6(ii), Table 2;
case 10(ii), Table 3) showing that the same parents
Table 3: Dose of carbamazepine taken by the mother at conception and severity of the adverse features observed in the child.
Dose (mg per day) Dysmorphic features Developmental delay Structural anomalies
18 F (i)m 400 1 0 0
39 UC (i)f 400 0 0 0
29 F (i)f 600 0 1 0
29 F (ii)m 600 1 0 1
24 F (ii)f 600 0 0 1
24 F (i) 800 – – – (M)
36 F (i)f 800 0 0 0
10 F (ii)m 800 0 0 0
22 F (i)f 800 0 0 1
18 F (ii)f 800 0 0 0
12 F (i)m 800 2 2 0
12 F (ii)f 800 2 1 0
8 F (i)f 800 0 0 1
8 F (ii)m 800 2 0 1
23 F (i)f 1000 1 0 0
3 F (i)m 1000 0 1 0
30 F (i)f 1000 1 1 0
32 F (i)f 1200 0 0 0
Mother—study acquisition number 3–39; epilepsy syndrome F: focal, UC: unclassified. Child—number of pregnancy (i)–(ii); m/f:
gender; adverse features 0: none, 1: mild, 2: moderate (M): miscarriage.
could produce normal children in the absence of a high
dose of VPS.
Monotherapy with carbamazepine
The daily dose of CBZ prescribed before conception
is shown in Table 3; it ranged from 400 to 1200 mg
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(mean±SD 778± 205, coefficient of variation 0.263,
N = 18). One woman with focal epilepsy (case 24(ii))
prescribed 600 mg per day, had low or undetectable
CBZ levels in plasma twice during her second preg-
nancy. Plasma CBZ was not measured in every patient
however.
The outcomes of individual pregnancies in the three
assessment areas are shown in Table 3. A moderate
adverse outcome in at least one assessment area was
found in three offspring.
There was no significant association between ad-
verse outcome and CBZ dose in any assessment area
(Table 5). Adverse features were absent or mild in all
but the three children who showed moderate dysmor-
phic features; one only of these children had delayed
development. This was moderate and affected mainly
speech and motor skills.
Distribution of CBZ dose was different from VPS
dose. The variance of VPS dose was significantly
greater (variance ratio F = 5.62, P < 0.01).
Monotherapy with other drugs
The phenytoin (seven cases) and lamotrigine (four
cases) monotherapy groups were small. Adverse
features were absent or mild. The baby exposed to
maternal monotherapy with ethosuximide showed no
abnormality.
Polytherapy
The polytherapy group included various combinations
of clobazam (CLB), ethosuximide (ESM), gabapentin
(GBP), lamotrigine (LTG), phenytoin (PHT), topira-
mate (TPM) or vigabatrin (VGB) with CBZ or VPS.
Table 4: Polytherapy: drugs taken by the mother at conception and severity of the adverse features observed in the child.
Drugs Dysmorphic features Developmental delay Structural anomalies
31 IG (i)f VPS∗ + CBZ 1 0 0
37 IG (i)m VPS + LTG 1 0 0
42 IG (i) VPS∗ + LTG – – 3 (T)
20 IG (i)m VPS + PHT 1 0 0
12 F (iii) CBZ + CLB – – – (M)
27 F (i)m CBZ + GBP 1 0 0
4 IG (i)m CBZ + ESM 1 1 1
4 IG (ii)f CBZ + ESM 1 0 1
38 F (i)f CBZ + LTG 0 0 1
43 F (i) CBZ + LTG – – – (I)
34 F (i)m CBZ + LTG + TPM 0 0 0
19 F (i) CBZ + PHT + VGB – – – (E)
21 F (i)f CBZ + GBP + VPS 1 1 0
Drugs—CBZ: carbamazepine, CLB: clobazam, ESM: ethosuximide, GBP: gabapentin, LTG: lamotrigine, PHT: phenytoin, TPM:
topiramate, VGB: vigabatrin, VPS: sodium valproate (∗ > 1000 mg per day). Mother—study acquisition number 4–43; epilepsy syndrome
F: focal, IG: idiopathic generalised. Child—number of pregnancy (i)–(iii); m/f: gender; adverse features 0: none, 1: mild, 2: moderate, 3:
severe, (M): miscarriage, (T): termination, (E): ectopic, (I): intrauterine death.
Individual drug combinations and pregnancy out-
comes are summarised in Table 4. Adverse features
were absent or mild except in case 42(i) where the
woman was receiving VPS 1200 mg per day with LTG
125 mg per day at conception. Spina bifida was seen
on anomaly scan and the pregnancy was terminated.
DISCUSSION
Comparison of Tables 2 and 3 shows that an adverse
outcome was observed more frequently in association
with VPS than with CBZ. Table 2 shows eight off-
spring exposed to VPS monotherapy, who had a mod-
erate or severe adverse outcome in at least one as-
sessment area. Table 3 by contrast shows only three
offspring exposed to CBZ monotherapy with a mod-
erate adverse outcome. The statistical significance of
this difference could not be tested formally because
the two monotherapy groups were not comparable;
they differed in composition (no retrospective cases in
the CBZ group and no women with idiopathic gener-
alised epilepsy) and in the distribution of drug doses.
A greater risk of adverse outcome with VPS has how-
ever also been observed by other investigators.
In a recent study of children with foetal anticon-
vulsant syndrome most had dysmorphic features and
delayed development. The majority (60%) had been
exposed to VPS alone compared with only 7% to
CBZ7. Dysmorphic features in the new-born, which
may ‘fade’ with time, are sometimes seen as no more
than curiosities but significant association with devel-
opmental delay in the present study suggests that they
may be markers for neurobehavioral problems, which
will emerge later in childhood.
Developmental delay is probably the most serious
adverse result of exposure to AED in utero. Koch
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et a1.8 conducted a small, controlled, prospective
study of pregnancy in women with epilepsy. The fre-
quency of neurological dysfunction at 6 years was
highest in the offspring exposed to VPS. Ohtsuka
et al.9 in a controlled prospective study also found a
relatively high risk of developmental delay in children
exposed to VPS.
Adab et al.10 obtained information on 594 children
in a retrospective survey of women with epilepsy.
The likelihood of additional educational needs was in-
creased in those exposed to VPS in utero; the odds
ratios relative to children with no AED exposure were
3.4 for VPS monotherapy and 2.5 for polytherapy in-
cluding VPS. The ratios for children exposed to CBZ
and to polytherapy without VPS did not differ signif-
icantly from 1.0.
Most AED studies do not assess dysmorphic fea-
tures or developmental delay but focus on struc-
tural anomalies. In a prospective study Canger et
al.11 found a higher prevalence of malformations
among babies exposed to VPS (10/77; 13%) than to
other AED (24/375; 6.4%; chi square, P < 0.05).
Steegers-Theunissen et al.12 made a controlled,
prospective study of 119 pregnancies in women with
epilepsy. Major malformations in the offspring of
those receiving monotherapy were more common
with VPS (3/19) than with CBZ (1/39) but the differ-
ence was not significant.
Fairgrieve et al.13 conducted a population based,
prospective study in pregnant women with epilepsy.
Prevalence of malformations was 20/400 (5%), ap-
proximately twice that in the general population. CBZ
monotherapy was more frequent than VPS in the ra-
tio of about 3:2. Despite this bias malformations were
more common with VPS (11) than with CBZ (6).
Not every investigator has found an adverse out-
come more frequently with VPS than with CBZ,
however. Samren et al.14 evaluated pooled data from
five prospective European studies. Despite finding a
significant association between VPS dose and major
congenital defect they failed to show a greater risk of
defect with VPS than with CBZ.
Our finding of a positive relationship between ad-
verse outcome and VPS dose (Tables 2 and 5) is con-
Table 5: Association between adverse outcome to pregnancy and dose of antiepileptic drug prescribed before conception.
Dysmorphic features Developmental delay Structural anomalies
Carbamazepine
Coefficient 0.036 0.213 −0.238
Probability P 0.891 0.412 0.358
Number of cases 17 17 17
Sodium valproate
Coefficient 0.645 0.459 0.535
Probability P 0.005 0.064 0.018
Number of cases 17 17 19
Coefficient: Spearman rank correlation coefficient, probability: significant at P < 0.05 (two tailed).
sistent with published work on structural defect. Such
a relationship was reported for spina bifida by Omtzigt
et al.15, for major congenital anomalies by Samren
et al.14, 16, and for congenital malformations in general
by Kaneko et al.17. New studies which could reveal
similar dose–response relationships for dysmorphic
features and developmental delay are awaited.
The failure to find a dose–response relationship for
CBZ in this study (Table 5) may reflect a difference
in prescribing rather than an intrinsic difference in
toxicity. The narrow spread of CBZ doses (Table 3)
decreases the likelihood of finding a dose–response
relationship. There was no clinic policy to recom-
mend an upper limit to CBZ dose before conception
but the diplopia and ataxia associated with high doses
probably create a natural upper limit. The ability of
patients by contrast to tolerate relatively high doses
of VPS without symptomatic toxicity may therefore
create a hazard in pregnancy.
The worst outcomes were seen in the offspring of
mothers prescribed VPS at doses above 1000 mg per
day (lower half of Table 2 and cases 31(i) and 42(i) in
Table 4). This was the only treatment group in which
adverse features in any of the three assessment areas
were severe. When the offspring exposed to such doses
(10 monotherapy, 2 polytherapy) were excluded, the
remaining 47 pregnancies showed a relatively low risk
of moderate adverse effects and no severely affected
cases (Fig. 1b). The ability of three mothers (retro-
spective cases in Table 2) to have healthy children,
after reduction of VPS dose or transfer to other treat-
ment, supports the premise that a high dose of VPS
played a major part in the earlier adverse outcome.
Several investigators have reported a high risk of
adverse outcome to pregnancy with maternal doses of
VPS above 1000 mg per day Samren et al.14; Omtzigt
et al.15; Kaneko et al.17 and the Guideline Develop-
ment Group of the Royal College of Physicians of
London2 recommended the avoidance of such doses
before conception.
We acknowledge the limitations of the study, which
was biased towards poor outcome by inclusion of pa-
tients with difficult-to-manage epilepsy and with ad-
verse outcomes to earlier pregnancies. The absence of
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controls and the awareness of maternal drug history
by the doctor assessing the children were also weak-
nesses.
There were also several opportunities for the con-
founding of relevant variables. For example idiopathic
generalised epilepsies, which are likely to have a ge-
netic basis, were more often treated with VPS than
with CBZ. Similarly, patients counselled before con-
ception were more likely to receive not only low dose
monotherapy but also folic acid.
CONCLUSION
Despite its limitations the results of this study add to
the growing body of evidence that VPS in pregnancy at
doses above 1000 mg per day carries a particular risk
of adverse outcome. Sodium valproate at such doses
should therefore be avoided when pregnancy is likely.
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